HomeCompareRSLS vs MO

RSLS vs MO: Dividend Comparison 2026

RSLS yields 51.02% · MO yields 9.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RSLS wins by $387.6K in total portfolio value
10 years
RSLS
RSLS
● Live price
51.02%
Share price
$3.92
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$415.3K
Annual income
$85,519.64
Full RSLS calculator →
MO
Altria Group Inc.
● Live price
9.11%
Share price
$44.80
Annual div
$4.08
5Y div CAGR
4.3%
Payout ratio
78%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.7K
Annual income
$4,052.72
Full MO calculator →

Portfolio growth — RSLS vs MO

📍 RSLS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRSLSMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RSLS + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RSLS pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RSLS
Annual income on $10K today (after 15% tax)
$4,336.73/yr
After 10yr DRIP, annual income (after tax)
$72,691.69/yr
MO
Annual income on $10K today (after 15% tax)
$774.11/yr
After 10yr DRIP, annual income (after tax)
$3,444.81/yr
At 15% tax rate, RSLS beats the other by $69,246.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RSLS + MO for your $10,000?

RSLS: 50%MO: 50%
100% MO50/50100% RSLS
Portfolio after 10yr
$221.5K
Annual income
$44,786.18/yr
Blended yield
20.22%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

RSLS
Analyst Ratings
1
Buy
2
Hold
Consensus: Hold
Altman Z
-24.1
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
+36.7% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RSLS buys
0
MO buys
0
No recent congressional trades found for RSLS or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRSLSMO
Forward yield51.02%9.11%
Annual dividend / share$2.00$4.08
Payout ratio50%78%
1-year div growth0%4.1%
5-year div CAGR0%4.3%
Portfolio after 10y$415.3K$27.7K
Annual income after 10y$85,519.64$4,052.72
Total dividends collected$332.9K$20.9K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: RSLS vs MO ($10,000, DRIP)

YearRSLS PortfolioRSLS Income/yrMO PortfolioMO Income/yrGap
1← crossover$15,802$5,102.04$10,740$949.88+$5.1KRSLS
2$24,443$7,534.83$11,601$1,086.84+$12.8KRSLS
3$37,047$10,892.59$12,608$1,250.75+$24.4KRSLS
4$55,069$15,429.12$13,792$1,448.20+$41.3KRSLS
5$80,358$21,434.63$15,190$1,687.69+$65.2KRSLS
6$115,215$29,231.87$16,851$1,980.28+$98.4KRSLS
7$162,450$39,169.84$18,838$2,340.48+$143.6KRSLS
8$225,437$51,615.25$21,230$2,787.44+$204.2KRSLS
9$308,160$66,942.06$24,130$3,346.72+$284.0KRSLS
10$415,251$85,519.64$27,676$4,052.72+$387.6KRSLS

RSLS vs MO: Complete Analysis 2026

RSLSStock

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Full RSLS Calculator →

MOConsumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →
📬

Get this RSLS vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RSLS vs SCHDRSLS vs JEPIRSLS vs ORSLS vs KORSLS vs MAINRSLS vs PMRSLS vs BTIRSLS vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.